Hospital
ST. Joseph Health Northern California, LLC
ST. Joseph Health Northern California, LLC was paid $8.03M by Medicaid between Jan 2018 and Sep 2019, across 219 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoST. JOSEPH HEALTH NORTHERN CALIFORNIA, LLC
EUREKA, CA 95501
EUREKA, CA 95501
33aNPI1891900635assigned 05/14/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.03M
24GClaims166,217
24DCodes billed219
24AFirst – last monthJan 2018 – Sep 2019
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#200 of 410
Median peer was paid$6.90M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,635 | $6.35M | |
| 2019 | 42,582 | $1.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 24,809 | 20,599 | $2.01M |
| 99201 | 5.7% | 3,543 | 2,489 | $460K | |
| J2704 | Injection, propofol, 10 mg | 4.2% | 1,443 | 1,324 | $334K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 721 | 691 | $300K |
| 97139 | 3.1% | 6,552 | 1,429 | $252K | |
| J3490 | Unclassified drugs | 2.7% | 15,313 | 7,651 | $218K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 2,165 | 1,932 | $210K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 1,412 | 776 | $190K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 910 | 859 | $188K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2.2% | 1,760 | 1,539 | $173K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.0% | 417 | 413 | $160K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.9% | 366 | 358 | $154K |
207 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 508 | $134K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 1,905 | $133K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 2,836 | $107K |
| 72141 | 1.2% | 236 | $98K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 518 | $88K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 281 | $88K |
| 95811 | 1.1% | 247 | $87K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.0% | 2,436 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,788 | $80K |
| 80053 | Comprehensive metabolic panel | <1% | 8,190 | $78K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 163 | $77K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 100 | $76K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 182 | $71K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 352 | $71K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,988 | $70K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 651 | $67K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 299 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,274 | $62K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 154 | $58K |
| 97799 | <1% | 1,461 | $56K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 954 | $53K |
| 73221 | <1% | 123 | $48K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,739 | $44K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 409 | $39K |
| 76830 | Ultrasound, transvaginal | <1% | 368 | $36K |
| 76770 | <1% | 341 | $35K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 583 | $34K |
| 97750 | <1% | 388 | $34K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 587 | $34K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 538 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 407 | $32K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 906 | $31K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 293 | $31K |
| 77066 | Tomosynthesis, mammo | <1% | 161 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,406 | $30K |
| 70486 | <1% | 122 | $30K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 833 | $29K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 570 | $29K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 231 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,871 | $27K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,764 | $26K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 238 | $25K |
| 80305 | <1% | 1,268 | $24K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,435 | $23K |
| 76641 | <1% | 164 | $23K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 781 | $23K |
| 83880 | <1% | 641 | $22K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,073 | $22K |
| 73630 | <1% | 623 | $21K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 737 | $21K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 737 | $21K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 103 | $20K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 534 | $19K |
| 73030 | <1% | 469 | $19K | |
| 90715 | <1% | 265 | $17K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 266 | $17K |
| 84484 | <1% | 1,383 | $16K | |
| 87400 | <1% | 1,099 | $16K | |
| 73610 | <1% | 403 | $15K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,689 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,168 | $15K |
| 72100 | <1% | 320 | $15K | |
| 93971 | <1% | 97 | $15K | |
| 73130 | <1% | 373 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 690 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,853 | $14K |
| 59025 | Fetal non-stress test | <1% | 415 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 42 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 282 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,643 | $13K |
| 76642 | <1% | 157 | $13K | |
| 93976 | <1% | 41 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 653 | $12K |
| 72040 | <1% | 314 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 131 | $12K |
| 83690 | <1% | 1,560 | $11K | |
| 73110 | <1% | 295 | $11K | |
| 76801 | <1% | 124 | $11K | |
| 93017 | <1% | 91 | $11K | |
| 96367 | <1% | 157 | $11K | |
| 71250 | <1% | 65 | $11K | |
| 76536 | <1% | 148 | $11K | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | <1% | 55 | $10K |
| 83605 | <1% | 791 | $10K | |
| 72110 | <1% | 143 | $9K | |
| 73562 | <1% | 273 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,058 | $9K |
| J1815 | Injection, insulin, per 5 units | <1% | 63 | $8K |
| 85027 | <1% | 1,243 | $8K | |
| 80061 | Lipid panel | <1% | 792 | $8K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $8K |
| 85610 | <1% | 2,187 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 180 | $8K |
| 73502 | <1% | 165 | $8K | |
| 87040 | <1% | 502 | $8K | |
| 86141 | <1% | 531 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 102 | $7K |
| 74018 | <1% | 268 | $7K | |
| 87186 | <1% | 787 | $7K | |
| 81001 | <1% | 2,193 | $7K | |
| 73564 | <1% | 176 | $6K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 25 | $6K |
| 81003 | <1% | 2,281 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 624 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 345 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 45 | $6K |
| 72050 | <1% | 99 | $6K | |
| 0450 | Emergency room services | <1% | 142 | $6K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 94 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 39 | $6K |
| 83735 | <1% | 932 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 456 | $5K |
| 84439 | <1% | 730 | $5K | |
| 10060 | <1% | 135 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 488 | $5K |
| 87081 | <1% | 867 | $5K | |
| 88142 | <1% | 1,243 | $5K | |
| 82962 | <1% | 909 | $4K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 114 | $4K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 99 | $4K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 202 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 122 | $4K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 52 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 419 | $3K |
| 85730 | <1% | 672 | $3K | |
| 85379 | <1% | 333 | $3K | |
| 96523 | <1% | 183 | $3K | |
| 87077 | <1% | 385 | $3K | |
| 96415 | <1% | 31 | $3K | |
| 96417 | <1% | 37 | $3K | |
| 86803 | <1% | 251 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 38 | $3K |
| 87070 | <1% | 325 | $3K | |
| 82805 | <1% | 104 | $3K | |
| 76870 | <1% | 26 | $2K | |
| 86762 | <1% | 235 | $2K | |
| 82607 | <1% | 192 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 158 | $2K |
| 73080 | <1% | 54 | $2K | |
| 80074 | <1% | 60 | $2K | |
| 29125 | <1% | 175 | $2K | |
| 87088 | <1% | 256 | $2K | |
| 73140 | <1% | 88 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 25 | $2K |
| 87147 | <1% | 440 | $2K | |
| 86140 | <1% | 473 | $2K | |
| 86901 | <1% | 650 | $2K | |
| 86900 | <1% | 651 | $2K | |
| 86850 | <1% | 719 | $2K | |
| 82728 | <1% | 163 | $2K | |
| 88304 | <1% | 256 | $2K | |
| 84702 | <1% | 102 | $2K | |
| 73090 | <1% | 48 | $2K | |
| 83540 | <1% | 281 | $1K | |
| 86592 | <1% | 316 | $1K | |
| 72072 | <1% | 28 | $1K | |
| 87340 | <1% | 173 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 288 | $1K |
| 12001 | <1% | 40 | $1K | |
| Z9725 | <1% | 24 | $1K | |
| Z7502 | <1% | 26 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 26 | $1K |
| 81002 | <1% | 545 | $946.85 | |
| 85007 | <1% | 331 | $925.25 | |
| 62323 | <1% | 24 | $922.39 | |
| 88341 | <1% | 13 | $920.26 | |
| 82951 | <1% | 100 | $902.00 | |
| 83550 | <1% | 150 | $877.43 | |
| 82570 | <1% | 158 | $826.46 | |
| 80076 | <1% | 153 | $811.63 | |
| 88342 | <1% | 52 | $739.58 | |
| 87205 | <1% | 209 | $694.36 | |
| 83615 | <1% | 153 | $694.08 | |
| 84100 | <1% | 158 | $650.51 | |
| 82550 | <1% | 95 | $630.79 | |
| 82784 | <1% | 59 | $617.96 | |
| 80164 | <1% | 58 | $577.18 | |
| 73590 | <1% | 15 | $575.01 | |
| 85651 | <1% | 212 | $523.48 | |
| 85652 | <1% | 249 | $503.14 | |
| 81025 | <1% | 162 | $498.53 | |
| 82140 | <1% | 27 | $484.22 | |
| 80069 | <1% | 54 | $465.74 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $458.33 |
| 84156 | <1% | 151 | $434.63 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $411.24 |
| 29515 | <1% | 28 | $397.60 | |
| 82378 | <1% | 28 | $386.96 | |
| 84153 | <1% | 21 | $383.86 | |
| 87420 | <1% | 153 | $358.02 | |
| 82746 | <1% | 32 | $355.43 | |
| 72081 | <1% | 13 | $345.42 | |
| 83516 | <1% | 12 | $315.42 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 13 | $305.20 |
| 86038 | <1% | 40 | $274.17 | |
| 82150 | <1% | 34 | $247.08 | |
| 88307 | <1% | 13 | $227.89 | |
| 82652 | <1% | 14 | $223.04 | |
| 82565 | <1% | 46 | $189.84 | |
| 84550 | <1% | 44 | $156.57 | |
| 84703 | <1% | 30 | $149.93 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 13 | $110.24 |
| 84403 | <1% | 12 | $107.00 | |
| 80047 | <1% | 17 | $91.56 | |
| 83001 | <1% | 12 | $86.76 | |
| 85014 | <1% | 19 | $47.09 | |
| 0250 | <1% | 54 | $10.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Parent organizationST. JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.